| Chapter 126 |
| 2022 -- S 2444 SUBSTITUTE A Enacted 06/21/2022 |
| A N A C T |
| RELATING TO FOOD AND DRUGS -- UNIFORM CONTROLLED SUBSTANCES ACT |
Introduced By: Senators Sosnowski, Rogers, DiPalma, and Murray |
| Date Introduced: March 01, 2022 |
| It is enacted by the General Assembly as follows: |
| SECTION 1. Section 21-28-2.08 of the General Laws in Chapter 21-28 entitled "Uniform |
| Controlled Substances Act" is hereby amended to read as follows: |
| 21-28-2.08. Contents of schedules. |
| Schedule I |
| (a) Schedule I shall consist of the drugs and other substances, by whatever official name, |
| common or usual name, chemical name, or brand name designated, listed in this section. |
| (b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the |
| following opiates, including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers |
| whenever the existence of the isomers, esters, ethers, and salts is possible within the specific |
| chemical designation: |
| (1) Acetylmethadol |
| (2) Allylprodine |
| (3) Alphacetylmethadol |
| (4) Alphameprodine |
| (5) Alphamethadol |
| (6) Benzethidine |
| (7) Betacetylmethadol |
| (8) Betameprodine |
| (9) Betamethadol |
| (10) Betaprodine |
| (11) Clonitazene |
| (12) Dextromoramide |
| (13) Difenoxin |
| (14) Diampromide |
| (15) Diethylthiambutene |
| (16) Dimenoxadol |
| (17) Dimepheptanol |
| (18) Dimethylthiambutene |
| (19) Dioxaphetyl butyrate |
| (20) Dipipanone |
| (21) Ethylmethylthiambutene |
| (22) Etonitazene |
| (23) Extoxerdine |
| (24) Furethidine |
| (25) Hydroxypethidine |
| (26) Ketobemidone |
| (27) Levomoramide |
| (28) Levophenacylmorphan |
| (29) Morpheridine |
| (30) Noracymethadol |
| (31) Norlevorphanol |
| (32) Normethadone |
| (33) Norpipanone |
| (34) Phenadoxone |
| (35) Phenampromide |
| (36) Phenomorphan |
| (37) Phenoperidine |
| (38) Piritramide |
| (39) Proheptazine |
| (40) Properidine |
| (41) Propiram |
| (42) Racemoramide |
| (43) Trimeperidone |
| (44) Tilidine |
| (45) Alpha-methylfentanyl |
| (46) Beta-hydroxy-3-methylfentanyl other names: |
| N-[1-(2hydroxy-2-phenethyl)-3-methyl-4piperidingyl]-Nphenylpropanamide |
| (47) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N- |
| phenylpropanamide) |
| (48) N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide, its optical, positional, and |
| geometric isomers, salts and salts of isomers (Other names: acetyl fentanyl) |
| (49) N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl] piperidin-4-yl]-N-phenyl propionamide |
| (Other names: beta-hydroxythiofentanyl) |
| (50) N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide (Other names: Butyryl fentanyl) |
| (51) N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide (Other names: Furanyl |
| fentanyl) |
| (52) 3,4-dichloro-N-[(1-dimethylamino) cyclohexylmethyl] benzamide (Other names: |
| AH-7921) |
| (53) 3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (Other names: |
| U-47700) |
| (54) 3-Methylbutyrfentanyl (Other names: 3-MBF) |
| (55) 4-Fluorobutyrfentanyl (Other names: 4-FBF, p-FBF) |
| (56) 4-Phenylfentanyl |
| (57) 4-Methoxybutyrfentanyl (Other names: 4-MeO-BF) |
| (58) Acrylfentanyl (Other names: acryloyfentanyl) |
| (59) Lofentanyl |
| (60) N-Methylcarfentanyl |
| (61) Ocfentanyl (INN, A-3217) |
| (63) 4-methoxymethylfentanyl (Other names: R-30490) |
| (64) 1-cyclohexyl-4-(1,2 diphenylethyl)piperazine) (Other names: MT-45, IC-6) |
| (c) Opium Derivatives. Unless specifically excepted or unless listed in another schedule, |
| any of the following opium derivatives, its salts, isomers, and salts of isomers whenever the |
| existence of the salts, isomers, and salts of isomers is possible within the specific chemical |
| designation: |
| (1) Acetorphine |
| (2) Acetyldihydrocodeine |
| (3) Benzylmorphine |
| (4) Codeine methylbromide |
| (5) Codeine-N-Oxide |
| (6) Cyprenorphine |
| (7) Desomorphine |
| (8) Dihydromorphine |
| (9) Etorphine (Except hydrochloride salt) |
| (10) Heroin |
| (11) Hydromorphinol |
| (12) Methyldesorphine |
| (13) Methylihydromorphine |
| (14) Morphine methylbromide |
| (15) Morphine methylsulfonate |
| (16) Morphine-N-Oxide |
| (17) Myrophine |
| (18) Nococodeine |
| (19) Nicomorphine |
| (20) Normorphine |
| (21) Pholcodine |
| (22) Thebacon |
| (23) Drotebanol |
| (d) Hallucinogenic Substances. Unless specifically excepted or unless listed in another |
| schedule, any material, compound, mixture, or preparation that contains any quantity of the |
| following hallucinogenic substances, or that contains any of its salts, isomers, and salts of isomers |
| whenever the existence of the salts, isomers, and salts of isomers is possible within the specific |
| chemical designation (for purposes of this subsection only, the term "isomer" includes the optical, |
| position, and geometric isomers): |
| (1) 3, 4-methylenedioxy amphetamine |
| (2) 5-methoxy-3, 4-methylenedioxy amphetamine |
| (3) 3, 4, 5-trimethoxy amphetamine |
| (4) Bufotenine |
| (5) Diethyltryptamine |
| (6) Dimethyltryptamine |
| (7) 4-methyl 2, 5-dimethoxyamphetamine |
| (8) Ibogaine |
| (9) Lysergic acid diethylamide |
| (10) Marihuana |
| (11) Mescaline |
| (12) Peyote. Meaning all parts of the plant presently classified botanically as Lophophora |
| Williamsii Lemair whether growing or not; the seeds of the plant; any extract from any part of the |
| plant; and any compound, manufacture, salt, derivative, mixture, or preparation of the plant, its |
| seeds or extracts. |
| (13) N-ethyl-3-piperidyl benzilate |
| (14) N-methyl-3-piperidyl benzilate |
| (15) Psilocybin |
| (16) Psilocyn |
| (17) Tetrahydrocannabinols. Synthetic equivalents of the substances contained in the plant, |
| or in the resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives, and their |
| isomers with similar chemical structure and pharmacological activity such as the following: delta |
| 1 cis or trans tetrahydrocannabinol, and their optical isomers. Delta 6 cis or trans |
| tetrahydrocannabinol and their optical isomers. Delta 3, 4 cis or trans tetrahydrocannabinol and |
| their optical isomer. (Since nomenclature of these substances is not internationally standardized, |
| compounds of these structures, regardless of numerical designation of atomic positions covered). |
| (18) Thiophene analog of phencyclidine. 1-(1-(2 thienyl) cyclo-hexyl) pipiridine: 2- |
| Thienyl analog of phencyclidine: TPCP |
| (19) 2,5 dimethoxyamphetamine |
| (20) 4-bromo-2,5-dimethoxyamphetamine, 4-bromo-2,5-dimethoxy-alpha- |
| methylphenethyamine: 4-bromo-2,5-DMA |
| (21) 4-methoxyamphetamine-4-methoxy-alpha-methylphenethylaimine: |
| paramethoxyamphetamine: PMA |
| (22) Ethylamine analog of phencyclidine. N-ethyl-1-phenylcyclohexylamine, (1- |
| phenylcyclohexyl) ethylamine, N-(1-phenylcyclophexyl) ethylamine, cyclohexamine, PCE |
| (23) Pyrrolidine analog of phencyclidine. 1-(1-phencyclohexyl)-pyrrolidine PCPy, PHP |
| (24) Parahexyl; some trade or other names: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9- |
| trimethyl-6H-dibenz o (b,d) pyran: Synhexyl. |
| (25) Salvia Divinorum (Salvinorin A or Divinorin A), meaning any extract from any part |
| of the plant, and any compound, salt derivative, or mixture of the plant or its extracts. This shall |
| not mean the unaltered plant. |
| (26) Datura stamonium (jimsom weed or datura), meaning any extract from any part of the |
| plant, and any compound, salt derivative, or mixture of the plant or its extracts. This shall not mean |
| the unaltered plant. |
| (e) Depressants. Unless specifically excepted or unless listed in another schedule, any |
| material, compound, mixture, or preparation that contains any quantity of the following substances |
| having a depressant effect on the central nervous system, including its salts, isomers, and salts of |
| isomers whenever the existence of the salts, isomers, and salts of isomers is possible within the |
| specific chemical designation: |
| (1) Mecloqualone. |
| (2) Methaqualone. |
| (3) 3-methyl fentanyl (n-(3methyl-1(2-phenylethyl)-4-piperidyl)-N-phenylpropanamide. |
| (4) 3,4-methyl-enedioxymethamphetamine (MDMA), its optical, positional, and geometric |
| isomers, salts, and salts of isomers. |
| (5) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical isomers, salts, and salts |
| of isomers. |
| (6) 1-(2-phenylethyl)-4-phenyl-4-acetyloxypiperidine (PEPAP), its optical isomers, salts, |
| and salts of isomers. |
| (7) N-(1-(1-methyl-2-phenyl)ethyl-4-piperidyl)-N-phenyl-acetamide (acetyl-alpha- |
| methylfentanyl), its optical isomers, salts, and salts of isomers. |
| (8) N-(1-(1-methyl-2(2-thienyl)ethyl-4-piperidyl)-N-phenylpropanami de (alpha- |
| methylthiofentanyl), its optical isomers, salts, and salts of isomers. |
| (9) N-(1-benzyl-piperidyl)-N-phenylpropanamide (benzyl-fentanyl), its optical isomers, |
| salts, and salts of isomers. |
| (10) N-(1-(2-hydroxy-2-phenyl)ethyl-4-piperidyl)-N-phenyl-propanamid e (beta- |
| hydroxyfentanyl), its optical isomers, salts, and salts of isomers. |
| (11) N-(3-methyl-1(2-hydroxy-2-phenyl)ethyl-4-piperidyl)-N-phenylpro panamide (beta- |
| hydroxy-3-methylfentanyl), its optical and geometric isomers, salts, and salts of isomers. |
| (12) N-(3-methyl)-1-(2-(2-thienyl)ethyl-4-piperidyl)-N-phenylpro-panamide (3- |
| methylthiofentanyl), its optical and geometric isomers, salts, and salts of isomers. |
| (13) N-(1-2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide (thenylfentanyl), its |
| optical isomers, salts, and salts of isomers. |
| (14) N-(1-(2(2-thienyl)ethyl-4-piperidyl-N-phenylpropanamide (thiofentanyl), its optical |
| isomers, salts, and salts of isomers. |
| (15) N-[1-(2-phenylethyl)-4-piperidyl]-N-(4-fluorophenyl)-propanamid e (para- |
| fluorofentanyl), its optical isomers, salts, and salts of isomers. |
| (16) Gamma hydroxybutyrate, HOOC-CH2-CH2-CH2OH, its optical, position, or |
| geometric isomers, salts, and salts of isomers. |
| (f) Stimulants. Unless specifically excepted or unless listed in another schedule, any |
| material, compound, mixture, or preparation that contains any quantity of the following substances |
| having a stimulant effect on the central nervous system, including its salts, isomers, and salts of |
| isomers: |
| (1) Fenethylline |
| (2) N-ethylamphetamine |
| (3) 4-methyl-N-methylcathinone (Other name: mephedrone) |
| (4) 3,4-methylenedioxy-N-methlycathinone (Other name: methylone) |
| (5) 3,4-methylenedioxypyrovalerone (Other name: MDPV) |
| (g) Any material, compound, mixture, or preparation that contains any quantity of the |
| following substances: |
| (1) 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497) |
| (2) 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol |
| (cannabicyclohexanol and CP-47,497 c8 homologue) |
| (3) 1-Butyl-3-(1 naphthoyl)indole, (JWH-073) |
| (4) 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200) |
| (5) 1-Pentyl-3-(1-napthoyl)indole, (JWH-018 and AM678) |
| (h) Synthetic cannabinoids or piperazines. Unless specifically excepted, any chemical |
| compound which is not approved by the United States Food and Drug Administration or, if |
| approved, which is not dispensed or possessed in accordance with state and federal law, that |
| contains Benzylpiperazine (BZP); Trifluoromethylphenylpiperazine (TFMPP); 1,1- |
| Dimethylheptyl-11-hydroxytetrahydrocannabinol (HU-210); 1-Butyl-3-(1-naphthoyl) indole; 1- |
| Pentyl-3-(1-naphthoyl) indole; dexanabinol (HU-211); or any compound in the following structural |
| classes: |
| (1) Naphthoylindoles: Any compound containing a 3-(1-naphthoyl)indole structure with |
| substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, |
| cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
| group, whether or not further substituted in the indole ring to any extent and whether or not |
| substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not |
| limited, to JWH-015, JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, and AM- |
| 2201; |
| (2) Phenylacetylindoles: Any compound containing a 3-phenylacetylindole structure with |
| substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, |
| cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
| group whether or not further substituted in the indole ring to any extent and whether or not |
| substituted in the phenyl ring to any extent. Examples of this structural class include, but are not |
| limited to, JWH-167, JWH-250, JWH-251, and RCS-8; |
| (3) Benzoylindoles: Any compound containing a 3-(benzoyl) indole structure with |
| substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, |
| cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
| group whether or not further substituted in the indole ring to any extent and whether or not |
| substituted in the phenyl ring to any extent. Examples of this structural class include, but are not |
| limited, to AM-630, AM-2233, AM-694, Pravadoline (WIN 48,098), and RCS-4; |
| (4) Cyclohexylphenols: Any compound containing a 2-(3-hydroxycyclohexyl)phenol |
| structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, |
| cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
| group whether or not substituted in the cyclohexyl ring to any extent. Examples of this structural |
| class include, but are not limited to, CP 47,497 and its C8 homologue (cannabicyclohexanol); |
| (5) Naphthylmethylindoles: Any compound containing a 1H-indol-3-yl-(1-naphthyl) |
| methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, |
| alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4- |
| morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and |
| whether or not substituted in the naphthyl ring to any extent. Examples of this structural class |
| include, but are not limited to, JWH-175, JWH-184, and JWH-185; |
| (6) Naphthoylpyrroles: Any compound containing a 3-(1-naphthoyl)pyrrole structure with |
| substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, |
| cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
| group whether or not further substituted in the pyrrole ring to any extent and whether or not |
| substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not |
| limited, to JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368; |
| (7) Naphthylmethylindenes: Any compound containing a 1-(1-naphthylmethyl)indene |
| structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, |
| cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
| group whether or not further substituted in the indene ring to any extent and whether or not |
| substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not |
| limited to, JWH-176; or |
| (8) Any other synthetic cannabinoid or piperazine which is not approved by the United |
| States Food and Drug Administration or, if approved, which is not dispensed or possessed in |
| accordance with state and federal law. |
| (i) Synthetic cathinones. Unless specifically excepted, any chemical compound which is |
| not approved by the United States Food and Drug Administration or, if approved, which is not |
| dispensed or possessed in accordance with state and federal law, not including bupropion, |
| structurally derived from 2-aminopropan-1-one by substitution at the 1-position with either phenyl, |
| naphthyl, or thiophene ring systems, whether or not the compound is further modified in one or |
| more of the following ways: |
| (1) By substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, |
| haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system by |
| one or more other univalent substituents. Examples of this class include, but are not limited to, 3,4- |
| Methylenedioxycathinone (bk-MDA); |
| (2) By substitution at the 3-position with an acyclic alkyl substituent. Examples of this |
| class include, but are not limited to, 2-methylamino-1-phenylbutan-1-one (buphedrone); |
| (3) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or |
| methoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure. |
| Examples of this class include, but are not limited to, Dimethylcathinone, Ethcathinone, and α- |
| Pyrrolidinopropiophenone (α-PPP); or |
| (4) Any other synthetic cathinone which is not approved by the United States Food and |
| Drug Administration or, if approved, is not dispensed or possessed in accordance with state or |
| federal law. |
| Schedule II |
| (a) Schedule II shall consist of the drugs and other substances, by whatever official name, |
| common or usual name, chemical name, or brand name designated, listed in this section. |
| (b) Substances, vegetable origin, or chemical synthesis. Unless specifically excepted or |
| unless listed in another schedule, any of the following substances whether produced directly or |
| indirectly by extraction from substances of vegetable origin, or independently by means of |
| chemical synthesis, or by a combination of extraction and chemical synthesis: |
| (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or |
| opiate excluding naloxone and its salts, and excluding naltrexone and its salts, but including the |
| following: |
| (i) Raw opium |
| (ii) Opium extracts |
| (iii) Opium fluid extracts |
| (iv) Powdered opium |
| (v) Granulated opium |
| (vi) Tincture of opium |
| (vii) Etorphine hydrochloride |
| (viii) Codeine |
| (ix) Ethylmorphine |
| (x) Hydrocodone |
| (xi) Hydromorphone |
| (xii) Metopon |
| (xiii) Morphine |
| (xiv) Oxycodone |
| (xv) Oxymorphone |
| (xvi) Thebaine |
| (2) Any salt, compound, derivative, or preparation that is chemically equivalent or identical |
| with any of the substances referred to in subdivision (1) of this subsection, except that these |
| substances shall not include the isoquinoline alkaloids of opium. |
| (3) Opium poppy and poppy straw. |
| (4) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any |
| salt, compound, derivative, or preparation that is chemically equivalent or identical with any of |
| these substances, except that the substances shall not include decocainized coca leaves or extraction |
| of coca leaves, which extractions do not contain cocaine or ecgonine. |
| (5) Concentrate of poppy straw (the crude extract of poppy straw in liquid, solid, or powder |
| form that contains the phenanthrine alkaloids of the opium poppy). |
| (c) Opiates. Unless specifically excepted or unless listed in another schedule, any of the |
| following opiates, including its isomers, esters, ethers, salts; and salts of isomers, esters, and ethers |
| whenever the existence of the isomers, esters, ethers, and salts is possible within the specific |
| chemical designation: |
| (1) Alphaprodine |
| (2) Anileridine |
| (3) Bezitramide |
| (4) Dihydrocodeine |
| (5) Diphenoxylate |
| (6) Fentanyl |
| (7) Isomethadone |
| (8) Levomethorphan |
| (9) Levorphanol |
| (10) Metazocine |
| (11) Methadone |
| (12) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane |
| (13) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic |
| acid |
| (14) Pethidine |
| (15) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine |
| (16) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate |
| (17) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid |
| (18) Phenaxocine |
| (19) Piminodine |
| (20) Racemethorphan |
| (21) Racemorphan |
| (22) Bulk Dextropropoxyphene (non-dosage forms) |
| (23) Suffentanil |
| (24) Alfentanil |
| (25) Levoalphacetylmethadol |
| (26) Carfentanil |
| (27) Remifentanil |
| (d) Stimulants. Unless specifically excepted or unless listed in another schedule, any |
| material, compound, mixture, or preparation that contains any quantity of the following substances |
| having a stimulant effect on the central nervous system: |
| (1) Amphetamine, its salts, optical isomers, and salts of its optical isomers. |
| (2) Methamphetamine, its salts, and salts of its isomers. |
| (3) Phenmetrazine and its salts. |
| (4) Methylphenidate. |
| (e) Depressants. Unless specifically excepted or unless listed in another schedule, any |
| material, compound, mixture, or preparation that contains any quantity of the following substances |
| having a depressant effect on the central nervous system, including its salts, isomers, and salts of |
| isomers whenever the existence of the salts, isomers, and salts of isomers is possible within the |
| specific chemical designation: |
| (1) Amobarbital |
| (2) Glutethimide |
| (3) Methyprylon |
| (4) Pentobarbital |
| (5) Phencyclidine |
| (6) Secobarbital |
| (7) Phencyclidine immediate precursors: |
| (i) 1-phencyclohexylamine |
| (ii) 1-piperidinocyclohexane-carbonitrile (PCC) |
| (8) Immediate precursor to amphetamine and methamphetamine: Phenylacetone. Some |
| other names: phenyl-2-propanone; P2P; benzyl methyl ketone; methyl benzone ketone. |
| Schedule III |
| (a) Unless specifically excepted or unless listed in another schedule, any material, |
| compound, mixture, or preparation that contains any quantity of the following substances having a |
| depressant effect on the central nervous system: |
| (1) Any substance that contains any quantity of a derivative of barbituric acid or any salt |
| of a derivative of barbituric acid. |
| (2) Chlorhexadol |
| (3) Lysergic acid |
| (4) Lysergic acid amide |
| (5) Sulfondiethylmethane |
| (6) Sulfonethylmethane |
| (7) Sylfonmethane |
| (8) Any compound, mixture, or preparation containing amobarbital, secobarbital, |
| pentobarbital, or any salt of them and one or more other active medicinal ingredients that are not |
| listed in any schedule. |
| (9) Any suppository dosage form containing amobarbital, secobarbital, pentobarbital, or |
| any salt of any of these drugs and approved by the Food and Drug Administration for marketing |
| only as a suppository. |
| (10) Ketamine, its salts, isomers, and salts of isomers. (Some other names for ketamine: |
| (+)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone). |
| (b) Unless specifically excepted or unless listed in another schedule, any material, |
| compound, mixture, or preparation containing limited quantities of any of the following narcotic |
| drugs, or any salts of them: |
| (1) Not more than one and eight tenths grams (1.8 gms.) of codeine per one hundred |
| milliliters (100 mls.) or not more than ninety milligrams (90 mgs.) per dosage unit, with an equal |
| or greater quantity of an isoquinoline alkaloid of opium. |
| (2) Not more than one and eight tenths grams (1.8 gms.) of codeine per one hundred |
| milliliters (100 mls.) or not more than ninety milligrams (90 mgs.) per dosage unit, with one or |
| more active, nonnarcotic ingredients in recognized therapeutic amounts. |
| (3) Not more than three hundred milligrams (300 mgs.) of dihydrocodeinone per one |
| hundred milliliters (100 mls.) or not more than fifteen milligrams (15 mgs.) per dosage unit, with |
| a fourfold or greater quantity of an isoquinoline alkaloid of opium. |
| (4) Not more than three hundred milligrams (300 mgs.) of dihydrocodeinone per one |
| hundred milliliters (100 mls.) or not more than fifteen milligrams (15 mgs.) per dosage unit, with |
| one or more active nonnarcotic ingredients in recognized therapeutic amounts. |
| (5) Not more than one and eight tenths grams (1.8 gms.) of dihydrocodeine per one hundred |
| milliliters (100 mls.) or not more than ninety milligrams (90 mgs.) per dosage unit, with one or |
| more active nonnarcotic ingredients in recognized therapeutic amounts. |
| (6) Not more than three hundred milligrams (300 mgs.) of ethylmorphine per one hundred |
| milliliters (100 mls.) or not more than fifteen milligrams (15 mgs.) per dosage unit, with one or |
| more active nonnarcotic ingredients in recognized therapeutic amounts. |
| (7) Not more than five hundred milligrams (500 mgs.) of opium per one hundred milliliters |
| (100 mls.) or per one hundred grams (100 gms.) or not more than twenty-five milligrams (25 mgs.) |
| per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts. |
| (8) Not more than fifty milligrams (50 mgs.) of morphine per one hundred milliliters (100 |
| mls.) per one hundred grams (100 gms.) with one or more active, nonnarcotic ingredients in |
| recognized therapeutic amounts. |
| (c) Stimulants. Unless specifically excepted or listed in another schedule, any material, |
| compound, mixture, or preparation that contains any quantity of the following substances having a |
| stimulant effect on the central nervous system, including its salts, isomers, and salts of the isomers |
| whenever the existence of the salts of isomers is possible within the specific chemical designation: |
| (1) Benzphetamine |
| (2) Chlorphentermine |
| (3) Clortermine |
| (4) Mazindol |
| (5) Phendimetrazine |
| (d) Steroids and hormones. Anabolic steroids (AS) or human growth hormone (HGH), |
| excluding those compounds, mixtures, or preparations containing an anabolic steroid that because |
| of its concentration, preparation, mixture, or delivery system, has no significant potential for abuse, |
| as published in 21 C.F.R. § 1308.34, including, but not limited to, the following: |
| (1) Chlorionic Chorionic gonadotropin, except for veterinary use and when that use is |
| approved by the Food and Drug Administration. |
| (2) Clostebol |
| (3) Dehydrochlormethyltestosterone |
| (4) Ethylestrenol |
| (5) Fluoxymesterone |
| (6) Mesterolone |
| (7) Metenolone |
| (8) Methandienone |
| (9) Methandrostenolone |
| (10) Methyltestosterone |
| (11) Nandrolone decanoate |
| (12) Nandrolone phenpropionate |
| (13) Norethandrolone |
| (14) Oxandrolone |
| (15) Oxymesterone |
| (16) Oxymetholone |
| (17) Stanozolol |
| (18) Testosterone propionate |
| (19) Testosterone-like related compounds |
| (20) Human Growth Hormone (HGH) |
| (e) Hallucinogenic substances. |
| (1) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in U.S. |
| Food and Drug Administration-approved drug product. (Some other names for dronabinol: (6aR- |
| trans)-6a, 7, 8, 10a-tetrahydro-6, 6, 9-trimethyl-3-pentyl-6H-dibenzo[b,d] pyra n-1-ol,or(-)-delta- |
| 9(trans)-tetrahydrocannabinol.) |
| Schedule IV |
| (1) Barbital. |
| (2) Chloral betaine |
| (3) Chloral hydrate |
| (4) Ethchrovynol |
| (5) Ethinamate |
| (6) Methohexital |
| (7) Meprobamate |
| (8) Methylphenobarbital |
| (9) Paraldehyde |
| (10) Petrichloral |
| (11) Phenobarbital |
| (12) Fenfluramine |
| (13) Diethylpropion |
| (14) Phentermine |
| (15) Pemoline (including organometallic complexes and chelates thereof). |
| (16) Chlordiazepoxide |
| (17) Clonazepam |
| (18) Clorazepate |
| (19) Diazepam |
| (20) Flurazepam |
| (21) Mebutamate |
| (22) Oxazepam |
| (23) Unless specifically excepted or unless listed in another schedule, any material, |
| compound, mixture, or preparation that contains any quantity of the following substances, including |
| its salts: |
| Dextropropoxyphene(alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propronox |
| ybutane). |
| (24) Prazepam |
| (25) Lorazepam |
| (26) Not more than one milligram (1 mg.) of difenoxin and not less than twenty-five (25) |
| micrograms of atropine sulfate per dosage unit. |
| (27) Pentazocine |
| (28) Pipradrol |
| (29) SPA (-)-1-dimethylamino-1, 2-diphenylethane |
| (30) Temazepam |
| (31) Halazepam |
| (32) Alprazolam |
| (33) Bromazepam |
| (34) Camazepam |
| (35) Clobazam |
| (36) Clotiazepam |
| (37) Cloxazolam |
| (38) Delorazepam |
| (39) Estazolam |
| (40) Ethyl Ioflazepate |
| (41) Fludizaepam |
| (42) Flunitrazepam |
| (43) Haloxazolam |
| (44) Ketazolam |
| (45) Loprazolam |
| (46) Lormetazepam |
| (47) Medazepam |
| (48) Nimetazepam |
| (49) Nitrazepam |
| (50) Nordiazepam |
| (51) Oxazolam |
| (52) Pinazepam |
| (53) Tetrazepam |
| (54) Mazindol |
| (55) Triazolam |
| (56) Midazolam |
| (57) Quazepam |
| (58) Butorphanol |
| (59) Sibutramine |
| Schedule V |
| (a) Any compound, mixture, or preparation containing any of the following limited |
| quantities of narcotic drugs, which shall include one or more non-narcotic active medicinal |
| ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable |
| medicinal qualities other than those possessed by the narcotic drug alone: |
| (1) Not more than two hundred milligrams (200 mgs.) of codeine per 100 milliliters (100 |
| mls.) or per one hundred grams (100 gms.). |
| (2) Not more than one hundred milligrams (100 mgs.) of dihydrocodeine per 100 milliliters |
| (100 mls.) or per one hundred grams (100 gms.). |
| (3) Not more than one hundred milligrams (100 mgs.) of ethylmorphine per 100 milliliters |
| (100 mls.) or per one hundred grams (100 gms.). |
| (4) Not more than two and five tenths milligrams (2.5 mgs.) of diphenixylate and not less |
| than twenty-five (25) micrograms of atropine sulfate per dosage unit. |
| (5) Not more than one hundred milligrams (100 mgs.) of opium per one hundred milliliters |
| (100 mls.) or per one hundred grams (100 gms.). |
| (b) Not more than five tenths milligrams (0.5 mgs.) of difenoxin and not less than twenty- |
| five (25) micrograms of atropine sulfate per dosage unit. |
| (c) Buprenorphine |
| (d) Unless specifically exempted or excluded or unless listed in another schedule, any |
| material, compound, mixture, or preparation that contains any quantity of the following substances |
| having a stimulant effect on the central nervous system, including its salts, isomers, and salts of |
| isomers: |
| (1) Propylhexedrine (except as benzedrex inhaler) |
| (2) Pyrovalerone. |
| SECTION 2. This act shall take effect upon passage. |
| ======== |
| LC004729/SUB A |
| ======== |